Obeticholic Acid
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522440

CAS#: 459789-99-2

Description: Obeticholic Acid (INT747; 6-ECDCA) is a novel derivative of cholic acid which acts as a potent and selective FXR agonist displaying anticholeretic activity in an in vivo rat model of cholestasis. It inhibits vascular smooth muscle cell inflammation and migration as well as promotes adipocyte differentiation and regulates adipose cell function in vivo.


Price and Availability

Size
Price

50mg
USD 150
500mg
USD 650
5g
USD 2650
50g
USD 5650
Size
Price

100mg
USD 250
1g
USD 850
10g
USD 3650
100g
USD 8650
Size
Price

200mg
USD 450
2g
USD 1450
20g
USD 4650

Obeticholic Acid purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 10g may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 522440
Name: Obeticholic Acid
CAS#: 459789-99-2
Chemical Formula: C26H44O4
Exact Mass: 420.32396
Molecular Weight: 420.63
Elemental Analysis: C, 74.24; H, 10.54; O, 15.21


Synonym: 6-Ethylchenodeoxycholic acid; Obeticholic acid; INT 747; INT-747; INT747; 6-ECDCA; Ocaliva.

IUPAC/Chemical Name: (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

InChi Key: ZXERDUOLZKYMJM-ZWECCWDJSA-N

InChi Code: InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1

SMILES Code: C[C@@H]([C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)CCC(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
291819


References

1: Armstrong MJ, Newsome PN. Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet. 2015 Jul 4;386(9988):28. doi: 10.1016/S0140-6736(15)61199-0. PubMed PMID: 26169862.

2: Neuschwander-Tetri BA, Van Natta ML, Tonascia J, Brunt EM, Kleiner DE. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply. Lancet. 2015 Jul 4;386(9988):28-9. doi: 10.1016/S0140-6736(15)61200-4. PubMed PMID: 26169861.

3: Musso G, Cassader M, Gambino R. Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet. 2015 Jul 4;386(9988):27. doi: 10.1016/S0140-6736(15)61198-9. PubMed PMID: 26169860.

4: Dong R, Zheng S, Chen G. The Appropriate Timing and Dose of Obeticholic Acid in Patients With Primary Biliary Cirrhosis. Gastroenterology. 2015 Aug;149(2):508. doi: 10.1053/j.gastro.2015.01.050. Epub 2015 Jun 29. PubMed PMID: 26136168.

5: Arrese M, Cabrera D, Barrera F. Obeticholic acid: expanding the therapeutic landscape of NASH. Ann Hepatol. 2015 May-Jun;14(3):430-2. PubMed PMID: 25864227.

6: Musso G. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost. Hepatology. 2015 Jun;61(6):2104-6. doi: 10.1002/hep.27772. Epub 2015 Apr 8. PubMed PMID: 25753820.

7: Wong VW, Wong GL, Chan FK. Is obeticholic Acid the solution to nonalcoholic steatohepatitis? Gastroenterology. 2015 Apr;148(4):851-2. doi: 10.1053/j.gastro.2015.02.044. Epub 2015 Feb 26. PubMed PMID: 25726736.

8: Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, Komuta M, Roskams T, Chatterjee S, Annaert P, Vander Elst I, Windmolders P, Trebicka J, Nevens F, Laleman W. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol. 2015 Feb;185(2):409-19. doi: 10.1016/j.ajpath.2014.10.009. Epub 2015 Jan 12. PubMed PMID: 25592258.

9: Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015 Apr;148(4):751-61.e8. doi: 10.1053/j.gastro.2014.12.005. Epub 2014 Dec 11. PubMed PMID: 25500425.

10: Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7. Erratum in: Lancet. 2015 Mar 14;385(9972):946. PubMed PMID: 25468160; PubMed Central PMCID: PMC4447192.